Involvement of NADPH oxidase in age-associated cardiac remodeling  by Wang, Mingyi et al.
Journal of Molecular and Cellular Cardiology 48 (2010) 765–772
Contents lists available at ScienceDirect
Journal of Molecular and Cellular Cardiology
j ourna l homepage: www.e lsev ie r.com/ locate /y jmccOriginal article
Involvement of NADPH oxidase in age-associated cardiac remodeling
Mingyi Wang a, Jing Zhang a, Simon J. Walker b, Rafal Dworakowski b, Edward G. Lakatta a, Ajay M. Shah b,⁎
a Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute of Aging, Baltimore, MD, USA
b King's College London British Heart Foundation Centre, Cardiovascular Division, London SE5 9PJ, UK⁎ Corresponding author. Cardiovascular Division, Th
College London, 125 Coldharbour Lane, London SE5 9N
fax: +44 2078485193.
E-mail address: ajay.shah@kcl.ac.uk (A.M. Shah).
0022-2828 © 2010 Elsevier Ltd.
doi:10.1016/j.yjmcc.2010.01.006
Open access under CC BY-a b s t r a c ta r t i c l e i n f oArticle history:
Received 23 July 2009
Received in revised form 6 January 2010
Accepted 6 January 2010







Oxidative stressIncreased activation of the renin–angiotensin–aldosterone system (RAAS) and an increase in oxidative stress
are both implicated in age-related cardiac remodeling but their precise interrelationship and linkage to
underlying molecular and cellular abnormalities remain to be deﬁned. Recent studies indicate that NADPH
oxidases are major sources of oxidative stress and are activated by the RAAS. This study investigated the
relationship between the NADPH oxidase system, age-related cardiac remodeling and its underlying
mechanisms. We studied male Fisher 344 cross Brown Norway rats aged 2 months (young rats), 8 months
(young adult rats) or 30 months (old rats). Aging-dependent increases in blood pressure, cardiomyocyte
area, coronary artery remodeling and cardiac ﬁbrosis were associated with increased myocardial NADPH
oxidase activity attributable to the Nox2 isoform. These changes were accompanied by evidence of local
RAAS activation, increased expression of connective tissue growth factor (CTGF) and TGF-β1, and a
signiﬁcant activation of MMP-2 and MT1-MMP. The changes in old rats were replicated in 8 month old rats
that were chronically treated with angiotensin II for 28 days. Increased RAAS activation may drive age-
related cardiac remodeling through the activation of Nox2 NADPH oxidase and subsequent increases in MMP
activation, ﬁbrosis and cardiomyocyte hypertrophy.e James Black Centre, King's
U, UK. Tel.: +44 2078485189;
NC-ND license. © 2010 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Aging substantially increases the risk of cardiovascular diseases
such as hypertension, atherosclerosis, left ventricular hypertrophy
(LVH), heart failure, atrial ﬁbrillation and stroke. The steep rise in
incidence of LVH and chronic heart failure with advancing age is
thought to be related at least in part to a continuum of structural and
functional alterations in the heart, which increase the propensity to
develop clinical cardiac disease [1,2]. Age-related cardiac remodeling
includes signiﬁcant changes in cardiac chamber stiffness and volumes
and in diastolic and systolic contractile function. These changes are
the result of major alterations in cellular and extracellular phenotype,
including cardiac myocyte hypertrophy, an increase in perivascular
and interstitial ﬁbrosis, remodeling of the extracellular matrix, and a
reduced capillary to myocyte ratio. In addition, increases in ventric-
ular afterload secondary to alterations in the peripheral vasculature
and in ventricular-vascular coupling also contribute to the cardiac
remodeling process.
The underlying mechanisms that drive age-related cardiac
remodeling remain to be fully deﬁned. Many experimental studies
have shown that increased activation of the renin-angiotensin-
aldosterone system (RAAS) is a prominent feature of age-relatedcardiac remodeling which may account for many of the phenotypic
changes that are observed [1,2]. An increase in oxidative stress is also
implicated in age-related cardiac remodeling [3,4], and aging is
indeed well recognized to be associated with increased production of
reactive oxygen species (ROS) in many different tissues [5]. Moreover,
it is increasingly appreciated that RAAS activation may itself be a
signiﬁcant driver of increased oxidative stress [6]. However, the
precise interrelationship between RAAS activation and increased
oxidative stress with respect to age-related cardiac remodeling and its
underlying cellular and extracellular abnormalities remains to be
clariﬁed.
In the last few years, studies in other cardiovascular settings have
established an important role for ROS-generating NADPH oxidases in
redox signaling pathways that underlie cardiovascular remodeling,
both experimentally and in humans [7]. The NADPH oxidases are
multi-protein enzyme complexes that generate superoxide through
the catalysis of electron transfer fromNADPH tomolecular oxygen [8].
Five oxidase isoforms have been identiﬁed each of which is based on a
distinct catalytic subunit, i.e., Nox1 to Nox5. Among these isoforms,
Nox1, Nox2 and Nox4 are known to be expressed in cardiovascular
cells. Nox5 has also been identiﬁed in human vascular cells but is not
expressed in rodents. In contrast to other sources of ROS, such as
mitochondria, xanthine oxidase and uncoupled nitric oxide synthases,
the generation of ROS by most NADPH oxidases is a regulated process
that is initiated by speciﬁc agonist stimulation. Notably, NADPH
oxidase family members are activated by angiotensin II, aldosterone,
endothelin I, cytokines (e.g., tumor necrosis factor α [TNFα] ), growth
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growth factor [PDGF] ), and mechanical forces [7,8]. The regulated
production of small amounts of ROS in response to such stimuli
appears to be ideally designed for involvement in redox signaling
pathways, and an involvement of NADPH oxidases in such signaling
has indeed been demonstrated in many studies [8,9]. Experimental
studies have conﬁrmed that NADPH oxidase-derived ROS play
important roles in the pathogenesis of cardiovascular pathologies
such as endothelial dysfunction, atherosclerosis, diabetic vasculo-
pathy, RAAS-related hypertension, and ischemic vascular remodeling
[6,7]. Recently, it has also been shown that NADPH oxidase activation
is involved in several types of cardiac remodeling, including
angiotensin II-induced cardiac hypertrophy, aldosterone-induced
cardiac ﬁbrosis and cardiac remodeling after myocardial infarction
(MI) [10–15]. In addition, increased myocardial NADPH oxidase
activity is found in human heart failure [16–18]. However, the
possible involvement of the NADPH oxidase system in age-related
cardiac remodeling remains unclear. In the current study, we have
investigated the relationship between the NADPH oxidase system,
age-related cardiac remodeling and some of its underlying mechan-
isms in a rodent aging model.
2. Material and methods
2.1. Animals
All animal experimentation was conducted in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory
Animals and using protocols approved by the institutional Animal Use
and Care Committee. Male Fisher 344 cross Brown Norway rats aged 2
months (young rats), 8 months (young adult rats) or 30 months (old
rats) were housed and maintained under identical conditions. A
cohort of young adult rats received angiotensin II (200 mg/kg/day)
via subcutaneous osmotic minipump (Alzet Corp., Cupertino, CA)
infusion for 28 days. Systolic blood pressure (SBP) was measured by
tail-cuff plethysmography in trained animals. At the end of the
experiments, animals were sacriﬁced by an overdose of sodium
pentobarbital and the hearts were immediately removed. Tissues for
histology were ﬁxed in 4% neutralized formalin, while those for
immunoblotting or other assays were frozen in liquid nitrogen and
stored at −70 °C.
2.2. Histology
Hearts sections were stained with hematoxylin and eosin (H&E),
toluidine blue, Picrosirius Red or Elastic van Gieson (EVG) and
quantitation of myocyte cross-sectional area and coronary vessel
histomorphometry were performed as described previously [19].
Immunohistochemistry was performed according to the biotin–
streptavidin kit instructions (Zymed Laboratories, Inc). Antigen was
recovered in citrate buffer at pH 6.0 (Zymed Laboratories, Inc) for 1–
3 min in a microwave oven. The slides were incubated overnight at
4 °C with primary antibodies. Smooth muscle cells in vessels were
identiﬁed by stainingwith an antibody againstα-smoothmuscle actin
and endothelial cells by staining with an anti-CD31 antibody.
2.3. In situ hybridization
Digoxigenin (DIG)-labeled MMP-2 (330 bp), TIMP-2 (361 bp),
and MT1-MMP(2338 bp) riboprobes were obtained from plasmid
cDNA (kindly provided by Michael Crow, Gerontology Research
Center, Baltimore, MD) by standard RNA synthesis, using SP6, T7, or
T3 RNA polymerase. Incorporation of DIG-conjugated uridine-5′-
triphosphate (UTP) was determined using a commercial kit (Boeh-
ringer Mannheim Corp) following the manufacturer's instruction. Insitu hybridization was performed by modiﬁcation of the methods
previously described [20].
Corresponding sense probes, hybridization buffer without probes,
and RNase digestion of tissue sections for 30 min before hybridization
were used as controls to determine speciﬁc hybridization.
2.4. Western blotting
Left ventricle lysates were resolved by SDS-PAGE and transferred
onto PVDFmembrane (Immobilon). The transferredmembranes were
incubated in PBS containing primary antibodies to MMP-2, TGF-β,
angiotensin converting enzyme (ACE), angiotensinogen, angiotensin
II, aldosterone, AT1 receptor, Nox2 or Rac1 at 4 °C for 24 h. HRP-
conjugated IgG (Amersham Pharmacia Biotech, Buckinghamshire, GB)
was used as secondary antibody and detected with SuperSignal West
Pico Chemiluminescent Substrate (Pierce Biotechnology, Rockford,
IL). Immunoblotting for α-sarcomeric actin was used as a protein
loading control. Band intensities were quantiﬁed by densitometric
analysis. We found in pilot studies that the protein levels of several
potential “housekeeping“ proteins changed with aging but α-
sarcomeric actin showed less alteration and had the additional
advantage of being a cardiomyocyte protein. Furthermore, in most
cases, changes in expression by immunoblotting were substantiated
by another method (e.g., immunohistochemistry).
2.5. In situ gelatin zymography
The presence of MMP-2 activity within the epicardial coronary
arteries in situ was detected as described [20]. Zymography was
repeated in the presence of an inhibitor antibody against MMP-2 to
determine the enzymatic speciﬁty of gel digestion.
2.6. NADPH oxidase activity
NADPH oxidase activity was assayed in heart homogenates as
NADPH-dependent superoxide generation measured using lucigenin-
enhanced chemiluminescence, as described previously [11]. Tissue
was homogenized in liquid nitrogen and placed into a 96-well
microplate luminometer together with dark-adapted lucigenin
(5 μmol/L), and NADPH (300 μmol/L) was added before recording
chemiluminescence. Superoxide production was expressed as arbi-
trary light units over 20 min. The effects of the following agents, pre-
incubated for 15 min, were used to assess potential sources of
superoxide production: diphenyleneiodonium (DPI, 10 μmol/L), a
ﬂavoprotein inhibitor; NG-nitro-L-arginine methyl ester (L-NAME,
100 μmol/L), a nitric oxide synthase inhibitor; oxypurinol (100 μmol/
L), a xanthine oxidase inhibitor; rotenone (2 μmol/L), a complex I
mitochondrial electron chain inhibitor; or apocynin (1 mmol/L). The
superoxide scavengers, Tiron (4,5-dihydroxy-1,3-benzene disulfonic
acid, 20 mmol/L) or superoxide dismutase (SOD, 200 U/mL), were
used to conﬁrm that the detected signal resulted from superoxide.
2.7. Real-time polymerase chain reaction (RT-PCR)
RNA was isolated from snap-frozen hearts using the RNeasy
Fibrous Tissue Kit (Qiagen). cDNA was synthesized using the
Omniscript kit (Qiagen) and random decamers. Real-time PCR was
performed using the ABI PRISM 7700 and SYBR Green master-mix
(Applied Biosystems). All quantitative assays used the universal
thermal cycling parameters (initial steps: 50 °C for 2 min, 95 °C for
10 min; and 95 °C for 15 s, 60 °C for 1 min, for 40 cycles). The level of
expression of all transcripts was determined using standard curves
from known amounts of template and normalized to β-actin. The
primer sequences were as follows:
Nox1 F: CCAAACGTGACAGTGATGTATGC, R: AGCTGAAGTTACCAT-
GAGAACCAA; Nox2 F: CGTATTGTGGGAGACTGGACTGA, R:
Fig. 1.NADPH-dependant ROS generation in heart homogenates, assessed by lucigenin-
enhanced chemiluminescence. (A) ROS generation in the absence of inhibitors. (B) ROS
generation in the presence of inhibitors in 8 month old rats treated with angiotensin II,
as described in the text. ⁎Pb0.05 cf. 8 month group; n=6/group.
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CAGA , R : GCGAAGGTAAGCCAGGACTGT ; p47phox F :
GCGTACGCTGCTGTTGAAGA, R: CGGTGATGTCCCCTTTCCT; p22phox
F: CCGTCTGCCTTGGCCATTG, R: GGTAGGTGGCTGCTTGATGGT; con-
nective tissue growth factor (CTGF) F: GCTGCCTACCGACTGGAAGAC,
R: GAACAGGCGCTCCACTCTG; β-actin F: CGTGAAAAGATGACCCA-
GATCA, R: TGGTACGACCAGAGGCATACAG.
2.8. Statistics
Analyses were performed using the SPSS 13 statistical package
(SPSS, Inc, Chicago, Il). Data were expressed as mean±SEM. The
comparisons between experimental groups were performed using
one-way ANOVA followed by a Scheffe post hoc test. Pb0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Age-related cardiac remodeling in the Fisher 344 cross Brown
Norway rat
SBP progressively increased with advancing age such that it was
approximately 30 mm Hg higher in 30 month compared to 8 month
rats (Supplementary Fig. 1A). There was no signiﬁcant change in the
heart weight over body weight ratio in old versus young adult rats
(Supplementary Fig. 1A) but the cardiomyocyte cross-sectional area
was signiﬁcantly higher in old animals (Supplementary Fig. 2),
indicating the development of hypertrophy. Aging was associated
with signiﬁcant remodeling of the epicardial coronary arteries.
Coronary artery thickness increased progressively from age 2 months
to 8 months to 30 months (Supplementary Fig. 1A) and this was
accompanied by a signiﬁcant decrease in both smooth muscle and
endothelial cell density (Supplementary Fig. 1B). In addition, there
was a substantial increase in perivascular ﬁbrosis and interstitial
cardiac ﬁbrosis as assessed by Picrosirius red or EVG staining
(Supplementary Fig. 3). Furthermore, the increased birefringence
pattern under polarized light in Picrosirius Red stained sections
(Supplementary Fig. 3, middle panels) suggested that much of the
increased collagen was abnormally cross-linked. Taken together, the
above data show typical changes of cardiac and coronary vascular
remodeling with advancing age.
Since RAAS activation is implicated in age-associated cardiac
remodeling and is a potent stimulus for NADPH oxidase activation, we
also studied a cohort of young adult rats that were chronically treated
with angiotensin II infusion. Angiotensin II-treated young adult rats
demonstrated similar cardiomyocyte hypertrophy (Supplementary
Fig. 2) and vascular remodeling (data not shown) to that found in old
rats.
3.2. Myocardial NADPH oxidase activity
Myocardial NADPH-dependent ROS generation was signiﬁcantly
increased in 30month old rats compared to 8month old rats (Fig. 1A).
Angiotensin II-treated young adult rats also had a similar increase in
ROS generation. The lucigenin signal was inhibited by Tiron or SOD in
all groups, conﬁrming superoxide as the measured ROS (Fig. 1B).
NADPH-dependent superoxide generation was abolished by the
ﬂavoprotein inhibitor DPI but was unaffected by L-NAME, oxypurinol
or rotenone (Fig. 1B), consistent with NADPH oxidase being the major
source of detected ROS.
3.3. NADPH oxidase subunit expression
In order to assess which NADPH oxidase isoforms may be
responsible for the increased oxidase activity, we measured the
expression of Nox1, Nox2 and Nox4 mRNA by real-time PCR. Nox1mRNA levels were at the limit of detection, consistent with previous
data in the rodent LV [7]. Therewas a signiﬁcant nearly 3-fold increase
in Nox2 mRNA expression in 30 month old rats compared to 8 month
old rats, while Nox2 mRNA levels were also signiﬁcantly elevated in
the angiotensin II-treated young adult group (Fig. 2A). Nox4 mRNA
expression levels were not signiﬁcantly different among the groups
(Fig. 2B). Since Nox2 oxidase activity requires several other protein
subunits, we also measured the expression of the p22phox and
p47phox subunits. No signiﬁcant differences in mRNA expression
level were found (Figs. 2C, D). Nox2 protein levels were signiﬁcantly
increased in the 30 month old rats and in the angiotensin II-treated
young adult group compared to untreated young adult rats by
immunoblotting (Supplementary Fig. 4). Immunohistochemistry also
conﬁrmed a robust increase in cardiomyocyte Nox2 expression in the
aging group (Fig. 3A). Since Rac1 is an important activator of Nox2
oxidase [6–8], we assessed Rac1 levels and localization. Rac1 protein
levels were substantially increased in 30 month old rats and in the
angiotensin II-treated 8 month old group compared to young adult
rats (Fig. 4A). Immunostaining of cardiac sections indicated that Rac1
levels were increased in cardiomyocytes with clear evidence of
enhanced staining at the sarcolemma (Fig. 4B).
3.4. Hormonal and cytokine mediators of remodeling
The expression of CTGF, which is strongly implicated in NADPH
oxidase-dependent cardiac remodeling [11,15], was signiﬁcantly
increased in the angiotensin II-infused 8 month old group and 30
month compared to 8month rats (Fig. 3B). We also found a signiﬁcant
increase in CTGF mRNA expression in 30 month old rats (data not
shown).
Fig. 2. mRNA expression of NADPH oxidase subunits Nox2, Nox4, p22phox and p47 phox. ⁎Pb0.05 cf. 8 month group; n=6/group.
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and activated TGF-β1 were signiﬁcantly elevated in the myocardium
of 30month old rats and in the angiotensin II-treated 8month old rats
compared to 8 month old untreated rats (Figs. 5A, B). Both these
agents not only promote remodeling but are known to activate
NADPH oxidase [7].
To establish evidence of local RAAS activation, we measured
protein levels of components of the RAAS in the myocardium.
Immunoblotting of LV samples showed that 30 month old rats and
angiotensin II-treated 8 month old rats had signiﬁcantly increased
levels of angiotensinogen, ACE and AT1 receptor compared to 8monthFig. 3. Representative heart sections immunostained for (A) Nox2old untreated rats (Figs. 5C, D). This was accompanied by evidence of
increased local angiotensin II levels by immunostaining (Supplemen-
tary Fig 5).3.5. MMP expression and activation
Alterations in MMP activity are centrally involved in cardiac
remodeling [21] while NADPH oxidase activation has been shown to
be upstream of the MMP activation that occurs in response to
angiotensin II stimulation [11,22] or during post-MI remodeling [15].and (B) CTGF. Similar results were obtained in 4 experiments.
Fig. 4. Changes in Rac1 expression in myocardium. (A) Immunoblots showing Rac1 expression and densitometric quantiﬁcation. ⁎Pb0.05 cf. 8 month group; n=4/group. (B)
Representative heart sections (×400 magniﬁcation). Similar results were obtained in 4 experiments.
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activation.
In situ hybridization studies demonstrated that the expression of
both MMP-2 and MT1-MMP (which is involved in TGFβ activation)
was increased in the intima and media of epicardial coronary arteries
of 30 month old rats, whereas TIMP-2 expression (which inhibits
MMP activity) was reduced (Fig. 6). Similar results were obtained
when immunostaining for these proteins was undertaken (Fig. 7). In
situ zymographic studies conﬁrmed that these changes in MMP/TIMP
expression were accompanied by an increase in MMP gelatinolytic
activity in the intima and media of epicardial coronary arteries of 30
month old rats (Supplementary Fig. 6). The in situ gelatinolytic
activity was almost completely inhibited by an antibody against
MMP-2, indicating that it mainly resulted fromMMP-2 activity. MMP2
activity assessed in total myocardial tissue homogenates by zymo-
graphy was also signiﬁcantly increased in the 30 month old rat group
and the 8month old rat group treatedwith angiotensin II as compared
to the 8 month old untreated group (Fig. 8).
4. Discussion
This study examined the possible involvement of NADPH oxidase
in aging-associated cardiac remodeling in a rodent model of aging.We
found that aged Fisher cross Brown Norway rats developed charac-
teristic phenotypic changes of cardiac remodeling [23,24] comprising
an increase in cardiomyocyte hypertrophy, interstitial and perivas-
cular ﬁbrosis, and a reduction in cellularity and a thickening of
coronary vessels. These changes were associated with an increase in
myocardial NADPH oxidase activity which was attributable mainly to
the Nox2 oxidase isoform and increased Rac1. The increases in NADPH
oxidase activity were accompanied by increased levels of aldosterone
and active TGFβ. Since both these agents (as well as angiotensin II) are
known to be activators of NADPH oxidases [6,7], it is likely that the
increased oxidase activity may have been attributable to increased
RAAS activation and increased TGFβ. Indeed, we found evidence of
local RAAS activation in myocardium of old rats in that there were
increased protein levels of ACE, angiotensinogen, angiotensin II andthe AT1 receptor. Consistent with the possibility that angiotensin II
was an important activator of NADPH oxidase, we found that young
adult rats chronically infused with angiotensin II also developed
increases in Nox2 expression, Rac1, NADPH oxidase activity and
cardiovascular remodeling. The increases in NADPH oxidase activity
were paralleled by a signiﬁcant increase in MMP expression and
activity, in line with previous ﬁndings that NADPH oxidase can drive
MMP activation [11,22]. Taken together, these results suggest that an
increase in Nox2 NADPH oxidase activity plays an important role in
aging-associated cardiac remodeling.
The NADPH oxidase family of enzymes is now well recognized as
a major source of ROS involved in cardiovascular pathophysiology
[6,7] and recent studies in gene-modiﬁed mice and in human heart
failure [10–18] support an involvement in cardiac remodeling. The
Nox2 isoform (also known as gp91phox) was ﬁrst described in
neutrophils but is also known to be expressed in cardiomyocytes,
endothelial cells, ﬁbroblasts and a range of inﬂammatory cells [6–8].
It is found as a heterodimer with a p22phox subunit, and requires
several cytosolic subunits (i.e., p47phox, p67phox, and Rac1) for its
activation. The Nox1 isoform is found mainly in vascular smooth
muscle cells while Nox4 is widely expressed in all cardiovascular cell
types. Whereas Nox1 and Nox2 are activated by agonists such as
angiotensin II, cytokines and growth factors, Nox4 oxidase is thought
to be constitutively active although its expression level can be
increased by TGFβ [8]. Prior studies in mice lacking Nox2 or
p47phox (which is necessary for Nox2 activation) suggest that this
isoform is especially important for cardiac remodeling [10–15,25],
although in vitro studies in cultured ﬁbroblasts have also implicated
Nox4 in the transformation of ﬁbroblasts to myoﬁbroblasts [26]. The
results of the present study suggest that it is the Nox2 isoform that is
involved in aging-associated cardiac remodeling. This conclusion is
further supported by the ﬁnding of increased Rac1 levels and
membrane location, known to be a key activator of the Nox2 oxidase
[6–8]. The precise Nox2-expressing cell types that are involved
remain to be fully established but immunohistochemistry clearly
showed an increase in Nox2 expression at least in cardiomyocytes.
Interestingly, increased Nox2 oxidase activation has recently also
Fig. 5. Changes in expression of local RAAS components and pro-ﬁbrotic factors. (A) Aldosterone expression—immunoblots are shown above with quantitation below. (B) TGFβ
expression. (C) Immunoblots showing expression levels of ACE, angiotensinogen (AGT) and AT1 receptor. (D) Mean densitometric data for ACE and AGT levels (AT1 data were not
quantiﬁed since levels were below detection limit in 8 month old rats). ⁎Pb0.05 cf. 8 month group (n=3/group).
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[27,28].
A key mechanism involved in tissue remodeling downstream of
NADPH oxidase-generated ROS is the activation of MMPs [11,15,22].
Altered MMP regulation is well established to be involved in aging-
related vascular remodeling [20], which is associated with a
signiﬁcant decrease in the numbers of both vascular smooth muscle
cells and endothelial cells, an increase in intimal and medial
thickness, and the perivascular accumulation of extracellular matrix
and collagen microﬁbers [1,20]. MMP dysregulation is also impli-
cated in the development of cardiac failure [21]. MMP activity is
regulated at multiple levels including transcription, secretion and
activation and is under the strict control of speciﬁc inhibitors, the
tissue inhibitors of MMPs (TIMPs). The change in balance between
MMPs and TIMPs in heart tissue and vessels toward an increase in
MMP activity results in increased proteolysis causing MMP-depen-
dent degradation of the extracellular matrix and is regarded as an
early mechanism in the progression to heart failure [21]. We found
that age-related NADPH oxidase activation and heart remodeling
were associated with increased mRNA and protein expression ofMMP-2 and a decrease in TIMP-2, leading to a disturbed balance and
an overall increase in gelatinolytic activity in old rats. In addition,
MT1-MMP expression was also increased in aged rats. Since MT1-
MMP is involved in TGFβ-1 activation, which in turn can lead to
NADPH oxidase activation and MMP activation, this could be an
important positive feedback loop that augments MMP activation and
cardiac remodeling. We found changes in overall myocardial MMP
activity as well as coronary vessel MMP activation, suggesting that
these changes may contribute to both cardiac and vascular
remodeling. Although no direct data on coronary vessel NADPH
oxidase activation were available in the present study, these results
raise the interesting question of crosstalk between coronary
remodeling and myocardial remodeling during aging and the
possibility that both may be driven by similar stimuli. In addition
to TGFβ-1, which is well known to be pro-ﬁbrotic, CTGF is a potent
pro-ﬁbrotic cytokine. Furthermore, myocardial Nox2 oxidase activa-
tion has previously been found to be upstream of increased CTGF
expression [11,15]. It was therefore of interest that the increased
age-associated NADPH oxidase activation and ﬁbrosis in the current
study were accompanied by increased CTGF expression.
Fig. 6. Representative sections of in situ hybridization for MMP-2, TIMP-2 andMT1-MMP. l, lumen; m, media. The blue color indicates mRNA signal and the red color indicates nuclei.
Similar results were obtained in 4 experiments.
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that links age-associated NADPH oxidase activation and cardiac
remodeling. Angiotensin II mediated oxidative stress has been
associated with age-dependent cardiomyopathy [3,4] and inhibition
of the RAAS was reported to ameliorate age-related progression of
cardiac hypertrophy [29]. As discussed previously, angiotensin II
drives cardiac ﬁbrosis and remodeling through NADPH oxidase
activation, in part through activation of mineralocorticoid receptors
[11]. Angiotensin II can also stimulate TGFβ mRNA expression and
promote its conversion to the active form [30] as well as enhancing
CTGF expression and thus synergistically increasing the pro-ﬁbrotic
effect of both cytokines. Other cytokines that could be involved in theFig. 7. Representative sections immunostained for MMP-2, TIMP-2 and MTprocess include TNF-α, which is implicated in aging-related pathology
possibly via an up-regulation of MMP levels [31,32]. TNF-α is also a
known activator of NADPH oxidase [33] and its possible involvement
in ageing-related cardiac remodeling therefore merits investigation.
4.1. Study limitations
We assessed NADPH oxidase activity in an ex vivo assay that does
not necessarily translate to similar increases in ROS production in vivo
nor does it exclude an important contribution by other sources of ROS
(e.g., mitochondria). However, the increase in Rac1 that was
documented provides supportive evidence of Nox2 activation in1-MMP. l, lumen; m, media. The brown color indicates protein signal.
Fig. 8.MMP2 activity in myocardial homogenates assessed by zymography. ⁎Pb0.05 cf.
8 month group (n=4–6/group).
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cantly inﬂuenced by the ambient antioxidant status, which was not
assessed in the current study. However, previous studies have
reported a signiﬁcant decrease in heart superoxide dismutase activity
in old compared to young Fischer 344 rats [34]. Such a reduction in
antioxidant activity, if present in the current study, would have been
an important contributing factor to enhanced NADPH oxidase-
dependent cardiac remodeling. Changes in protein expression levels
assessed by immunoblotting in this study (e.g., aldosterone) could
potentially be confounded by alterations in the levels of the
“housekeeping” protein used for normalization. However, the results
were generally backed up by a second method (e.g., immunohisto-
chemistry, activity assays) and/or the quantiﬁcation of related
molecules. Finally, more deﬁnitive evidence for an involvement of
NADPH oxidase-derived ROS in aging-associated cardiac remodeling
would be provided by studies in appropriate gene-modiﬁed models
and/or intervention studies.
In conclusion, this study suggests that the Nox2 NADPH oxidase
may play an important role in aging-associated cardiac remodeling by
enhancing MMP activation, the expression of pro-ﬁbrotic factors such
as CTGF and TGFβ, and cardiomyocyte hypertrophy. Since NADPH
oxidases are activated by multiple factors, including angiotensin II,
aldosterone, endothelin-1 and cytokines, it is arguable that they may
be a suitable therapeutic target for the prevention of aging-related
cardiac remodeling in addition to targeting the individual agonists
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